RHHBY News and Press, Roche Holding Ltd ADR

– After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss in placebo -1.2%; p < 0.001) 1 – – Pharmacokinetic data supports a once-daily oral dosing regimen for CT-996 1 – – The safety ...

2024-07-12 04:12:28 ET More on Amgen Amgen: Biotech Leader Riding High On Obesity Drug Euphoria (Downgrade) Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum Amgen: You Haven't Seen Anything Yet Lilly, Novo Nordisk to dominate weight lo...

Remix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration PR Newswire The collaboration leverages Remix's REMaster ™ platform to discover novel drugs for a diverse range of target classes Remix is eligible to receive up to ...

– The FDA has approved updates to Susvimo, which will be available to U.S. retina specialists and patients with wet AMD in the coming weeks – – Susvimo offers the first alternative to regular eye injections that are standard of care for wet AMD, which impacts 1.5 mill...

2024-07-05 15:04:46 ET More on Novo Nordisk Novo Nordisk: Buy On Dips Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk’s Ozempic, Wegovy linked to eye diso...

2024-07-05 08:13:15 ET More on Roche Roche: Obesity Treatment's Promise Isn't Enough More Of The Same Isn't Good Enough For Roche Roche Is Joining The Obesity Party But Questions Remain Roche's setback in lung cancer trial sends anti-TIGIT developers lower ...

2024-07-05 07:18:27 ET More on Roche Roche: Obesity Treatment's Promise Isn't Enough More Of The Same Isn't Good Enough For Roche Roche Is Joining The Obesity Party But Questions Remain Roche's crovalimab wins FDA approval for paroxysmal nocturnal hemoglobinu...

– Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness – – Designed to simplify administration, Vabysmo PFS provides retina specialists a ready-to-use option – ...

2024-07-04 12:45:03 ET Summary Novo Nordisk's Ozempic continues gaining popularity in weight management and diabetes markets, along with Wegovy, raising the question of whether the same can be hoped for the stock. There's a lot to like about the company. It's seeing robust sales g...

2024-07-04 11:30:00 ET Summary This article will present an in-depth analysis of drugs being developed to combat obesity and related diseases. Pharmaceutical companies are highly interested in the global obesity treatment market, which is expected to exceed $100 billion by 2030. ...